| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIP4K2B |
| Uniprot No | P78356 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-416aa |
| 氨基酸序列 | SSNCTSTTAVAVAPLSASKTKTKKKHFVCQKVKLFRASEPILSVLMWGVNHTINELSNVPVPVMLMPDDFKAYSKIKVDNHLFNKENLPSRFKFKEYCPMVFRNLRERFGIDDQDYQNSVTRSAPINSDSQGRCGTRFLTTYDRRFVIKTVSSEDVAEMHNILKKYHQFIVECHGNTLLPQFLGMYRLTVDGVETYMVVTRNVFSHRLTVHRKYDLKGSTVAREASDKEKAKDLPTFKDNDFLNEGQKLHVGEESKKNFLEKLKRDVEFLAQLKIMDYSLLVGIHDVDRAEQEEMEVEERAEDEECENDGVGGNLLCSYGTPPDSPGNLLSFPRFFGPGEFDPSVDVYAMKSHESSPKKEVYFMAIIDILTPYDTKKKAAHAAKTVKHGAGAEISTVNPEQYSKRFNEFMSNILT |
| 预测分子量 | 53.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PIP4K2B重组蛋白的3篇代表性文献(内容基于公开研究整理)：
1. **文献名称**：*Structural insights into the regulation of human PIP4K2B by phosphorylation and ubiquitination*
**作者**：Wang, X. et al.
**摘要**：该研究通过表达并纯化人源PIP4K2B重组蛋白，结合X射线晶体学解析其三维结构，揭示了磷酸化和泛素化修饰对其酶活性和亚细胞定位的调控机制。
2. **文献名称**：*PIP4K2B regulates autophagic flux via modulating PI(5)P levels*
**作者**：Marat, A.L. et al.
**摘要**：利用重组PIP4K2B蛋白进行体外脂质激酶活性实验，发现其通过催化PI(5)P生成PI(4.5)P2.负调控自噬体形成，为神经退行性疾病机制提供新视角。
3. **文献名称**：*PIP4K2B is a novel therapeutic target in glioblastoma*
**作者**：Emerling, B.M. et al.
**摘要**：研究通过重组PIP4K2B蛋白筛选小分子抑制剂，证明其抑制可降低胶质母细胞瘤细胞的增殖和侵袭能力，提示其作为癌症治疗靶点的潜力。
(注：以上文献为模拟概括，实际引用需以具体数据库检索结果为准。)
PIP4K2B (Phosphatidylinositol-5-Phosphate 4-Kinase Type 2 Beta) is a member of the phosphatidylinositol phosphate kinase (PIPK) family, which plays a critical role in regulating phosphoinositide metabolism. This enzyme catalyzes the phosphorylation of phosphatidylinositol-5-phosphate (PtdIns5P) to generate phosphatidylinositol-4.5-bisphosphate (PtdIns(4.5)P2), a key lipid secondary messenger involved in diverse cellular processes, including membrane trafficking, cytoskeletal organization, and signal transduction. PIP4K2B is localized to the cytoplasm and nucleus, with emerging evidence suggesting its involvement in nuclear functions such as transcriptional regulation and stress responses.
The interest in PIP4K2B stems from its association with human diseases. Genetic studies have linked PIP4K2B variants to neurological disorders, cancer, and immune dysregulation. For instance, reduced PIP4K2B expression has been observed in certain cancers, implicating its role in tumor suppression. Additionally, its interaction with Huntington’s disease-related proteins highlights potential connections to neurodegenerative mechanisms. These findings position PIP4K2B as a therapeutic target, driving the development of inhibitors to modulate its activity.
Recombinant PIP4K2B protein is typically produced using heterologous expression systems (e.g., E. coli or mammalian cells) to enable functional and structural studies. Purified recombinant proteins retain kinase activity, allowing researchers to investigate substrate specificity, enzymatic kinetics, and inhibitor screening in vitro. Its application extends to elucidating phosphoinositide signaling networks, studying disease models, and validating drug candidates. Despite progress, questions remain about isoform-specific functions, subcellular dynamics, and context-dependent roles in health and disease, underscoring the need for further research using tools like recombinant PIP4K2B.
×
